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Clinics and pathology 
Disease 
B-cell acute lymphoblastic leukaemia (B-ALL) 
Phenotype/cell stem origin 
Pre-B ALL: CD10+ in 14 of 15 cases, CD19+ probably 
in the remaining case. 
Epidemiology 
15 cases available: 9 male and 6 female patients; 
mediane age was 16 years (range: 6 - 48 years). 
Clinics 




Prognosis looks fair (see survival curve). 
Cytogenetics 
Cytogenetics morphological 
Major karyotypic anomalies were seen in 13 of 15 
cases, an i(9q) in 10/15 cases (a rather rare anomaly 
otherwise), +5 in 5/15, and del(13q) in 3/15. The 
syndrome is therefore very homogeneous, at the 
clinical, cytological, and cytogenetic levels. 
Genes involved and proteins 
Note 
Deletion of CDKN2A and PAX5 was found in 10 of 10 






Member of the ID gene family: "Inhibitors of DNA 
binding". They are transcription factors which act as 
transcription inhibitory proteins. They are basic helix-
loop-helix (bHLH) proteins which contain the bHLH 
dimerization domain, but lack the DNA binding 
domain. They form heterodimers with other bHLH 
proteins and inhibit them. ID4 may play an important 
suppressive role in tumor progression, and its silencing 
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No hybrid gene, but juxtaposition of ID4 to the IGH 
enhancer, leading to ID4 overexpression. 
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